Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function

Healthy Clinical Trial

Official title:

Effects of Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05538247
• Other study ID #: 22-003898
• Status: Recruiting
• Phase: Early Phase 1
• Start date: April 13, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: March 2024
• Source: Mayo Clinic
• Contact: Monique Torres
• Phone: 507-538-6599
• Email: torres.monique[@]mayo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to assess the effects of S. boulardii CNCM I-745 compared to placebo on impaired intestinal permeability, which is the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall into the rest of the body.

Description:

This placebo-controlled parallel group clinical study in healthy adults from the general population aims to investigate whether oral supplementation with S. boulardii CNCM I-745 could strengthen the intestinal barrier function and counteract the acute NSAID-induced hyperpermeability. Indomethacin will be used short term to increase intestinal permeability. The primary objective of the study is to assess the effects of S. boulardii CNCM I-745 on this impaired intestinal permeability.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 56
• Est. completion date: December 31, 2024
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

• Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination).

• With a body mass index (BMI) comprised between 18 and 35 kg/m^2 and weight > 50 kg at Screening.

• Able to comply with study requirements and to provide signed informed consent.

• Has signed the informed consent form before beginning any study procedure.

• Regular defecation (frequency and stool consistency, with at least about three bowel movements a week).

• For women of childbearing potential:

• A negative urine pregnancy test immediately prior to starting the study treatment;

• Agreement to comply with approved methods of contraception during the whole study: unless they meet the criteria of post-menopausal; i.e., 12 months of spontaneous amenorrhea, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner, should use one or more of the following acceptable methods of contraception that should be maintained throughout the study:

• Surgical sterilization;

• Hormonal contraception (implantable, patch, oral, intra-muscular);

• Intra-uterine device;

• Double barrier method (diaphragm plus condom);

• At the discretion of the investigator, total abstinence is acceptable in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance.

Exclusion Criteria:

• History of hypersensitivity to the study treatments (active substance or excipients), brewer's or baker's yeast.

• Contraindication and special warning to the study treatments according to the Summary of Product Characteristics (SmPCs).

• History of chronic constipation with passage of fewer than 3 spontaneous bowel movements per week on average.

• History of chronic or recurrent diarrhea with spontaneous unformed bowel movements equivalent to or more often than 3 times daily.

• Prior gastrointestinal surgery (apart from appendectomy or cholecystectomy performed at least more than one year ago).

• History of Clostridium difficile infection.

• Active gastrointestinal disease.

• Known chronic or recurrent systemic disorder (including diabetes and hypertension) that may interfere with the study treatment evaluation.

• Associated immune deficiency.

• Severe hepatic or renal impairment.

• Clinically relevant abnormalities in results of laboratory tests as per Investigator's judgement.

• Patients with a central venous catheter.

• Oral or systemic antibacterial therapy during the 3 months prior to study enrollment.

• NSAIDs and proton pump inhibitor treatment longer than 1 week, within 3 months prior to study enrollment.

• Steroids within 6 weeks prior to study enrollment.

• Use of medications affecting gastrointestinal transit or permeability within 7 days prior to the testing.

• Use of artificial sweeteners, lactulose, mannitol within 2 days prior to the testing and during the 24 h testing period.

• New prescription medications during the 2 weeks prior to study enrollment.

• Use of probiotics or drugs that alters gut microbiota or function, during 4 weeks prior to study enrollment.

• Intake of antifungals within 14 days prior to study enrollment.

• Substantial changes in eating habits within 30 days prior to receiving the first dose of IMP product, as assessed by the Investigator.

• Current smoker.

• History or presence of drug or alcohol abuse.

• Inability to abstain from intensive muscular effort the day before the intestinal permeability test.

• Breast-feeding woman.

• Patients enrolled in another clinical trial within the past 30 days.

• Patients not able to fill in the study questionnaires.

• Any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Indomethacin
Immediate release oral capsules 50 mg, 3 times a day for 6 days

Dietary Supplement:
• S. boulardii CNCM I-745
Two 250 mg capsules orally twice daily for 14 days

Drug:
• Placebo
Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Permeability assays	Change in intestinal permeability parameters urinary lactulose and 13C (13carbon) mannitol in 0-2 hrs, 2-8 hrs, 8-24 hr urine collection	Baseline, 2 hrs, 8 hrs, 24 hours
Primary	Change in serum zonulin	Circulating zonulin will be measured by ELISA (Immundiagnostik AG) reported in ng/mL	Baseline, after intervention approximately 14 days
Primary	Change in serum claudin	Serum Claudin 1, 2, 3, 4, 5 and 8 will be measured by ELISAs (Enzyme-Linked Immunosorbent Assay)	Baseline, after intervention approximately 14 days
Primary	Change in fecal calprotectin	Measured by ELISAs (Enzyme-Linked Immunosorbent Assay) from fecal samples reported in micrograms per milligram (µg/g)	Baseline, day 7 (+/-1), day 14 (+/-1) and day 20 (placebo group only)
Primary	Change in serum C-reactive protein (CRP)	Measured by immuno-turbidimetric assay on an automated clinical chemistry analyzer reported in mg/L	Baseline, day 7 (+/-1), day 14 (+/-1) and day 20 (placebo group only)
Primary	Change in Gastrointestinal Symptom Rating Scale (GSRS) scores	Measured by validated disease-specific questionnaire Gastrointestinal Symptom Response Scale (GSRS) used to evaluate common symptoms of gastrointestinal disorders. 15-item self-reported questionnaire related to signs and symptoms experienced by the subject during the past week, each rated on a seven-point Likert scale from no discomfort (score = 1) to very severe discomfort (score = 7). Total score is comprised between 15 and 105;	Baseline, day 7 (+/-1), day 14 (+/-1) and day 20 (placebo group only)